Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study
Sign Up to like & getrecommendations! Published in 2020 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofaa097
Abstract: Abstract Background Bezlotoxumab is approved for prevention of recurrence of Clostridioides difficile infection (CDI) in adults receiving standard of care (SoC) therapy based on findings from MODIFY clinical trials. However, utilization practices and validation of… read more here.
Keywords: real world; difficile infection; bezlotoxumab; clostridioides difficile ... See more keywords
Efficacy and Safety of Monoclonal Antibodies Against Clostridioides difficile Toxins for Prevention of Recurrent Clostridioides difficile Infection
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Gastroenterology"
DOI: 10.1097/mcg.0000000000001330
Abstract: Supplemental Digital Content is available in the text. Background: Clostridioides difficile infection is one of the most common health care-associated infections. To reduce the recurrent Clostridioides difficile infection (rCDI), monoclonal antibodies against Clostridioides difficile toxin… read more here.
Keywords: difficile infection; clostridioides difficile; recurrent clostridioides; bezlotoxumab ... See more keywords
Genetic Association Reveals Protection against Recurrence of Clostridium difficile Infection with Bezlotoxumab Treatment
Sign Up to like & getrecommendations! Published in 2020 at "mSphere"
DOI: 10.1128/msphere.00232-20
Abstract: Clostridium difficile infection is associated with significant clinical morbidity and mortality; antibacterial treatments are effective, but recurrence of C. difficile infection is common. In this genome-wide association study, we explored whether host genetic variability affected… read more here.
Keywords: difficile infection; recurrence; infection; association ... See more keywords
Clinicians should assess the benefits and risks of using bezlotoxumab for reducing the risk of recurrent Clostridium difficile infection
Sign Up to like & getrecommendations! Published in 2017 at "Evidence-Based Medicine"
DOI: 10.1136/ebmed-2017-110722
Abstract: Commentry on: Wilcox MH, Gerding DN, Poxton IR, et al . Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. N Engl J Med 2017;376:305–317. Clostridium difficile is an anaerobic gram-positive spore-forming bacillus that plays a… read more here.
Keywords: difficile infection; clostridium difficile; bezlotoxumab; recurrent clostridium ... See more keywords